Can probiotics improve efficiency and safety profile of triple Helicobacter pylori eradication therapy? A prospective randomized study.

Background/Aim Some studies suggest the benefit of applying different probiotic strains in combination with antibiotics in the eradication of Helicobacter pylori (H. pylori) infection. The aim of this study was to evaluate the effect of co-administration of multiple probiotic strains with triple H. pylori eradication therapy. This prospective study included 167 patients with dyspeptic symptoms and chronic gastritis who were diagnosed with H. pylori infection and randomized into two groups. The group I of 77 patients underwent triple eradication therapy, for 7 days, with lansoprazole, 2 × 30 mg half an hour before the meal, amoxicillin 2 × 1.000 mg per 12 hours and clarithromycin 2 × 500 mg per 12 hours. After the 7th day of the therapy, lansoprazole continued at a dose of 30 mg for half an hour before breakfast for 4 weeks. The group II of 90 patients received the same treatment as the patients of the group I, with the addition of the probiotic cultures in the form of a capsule comprising Lactobacillus Rosell-52, Lactobacillus Rosell-11, Bifidobacterium Rosell-1755 and Saccharomyces boulardii, since the beginning of eradication for 4 weeks. Eradication of H. pylori infection control was performed 8 weeks after the therapy by rapid urease test and histopathologic evaluation of endoscopic biopsies or by stool antigen test for H. pylori. Eradication of H. pylori infection was achieved in 93.3% of the patients who received probiotics with eradication therapy and in 81.8% of patients who were only on eradication therapy without probiotics. The difference in eradication success was statistically significant, (p < 0.05). The incidence of adverse effects of eradication therapy was higher in the group of patients who were not on probiotic (28.6%) than in the group that received probiotic (17.7%), but the difference was not statistically significant. Multiple probiotic strains addition to triple eradication therapy of H. pylori achieves a significantly better eradication success, with fewer side effects of antibiotics.

[1]  J. Wu,et al.  Lactobacillus pentosus strain LPS16 produces lactic acid, inhibiting multidrug-resistant Helicobacter pylori. , 2016, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.

[2]  C. O'Morain,et al.  Treatment of Helicobacter pylori Infection 2014 , 2014, Helicobacter.

[3]  V. Papastergiou,et al.  Treatment of Helicobacter pylori infection: meeting the challenge of antimicrobial resistance. , 2014, World journal of gastroenterology.

[4]  Guo-Xin Zhang,et al.  Is levofloxacin-based triple therapy an alternative for first-line eradication of Helicobacter pylori? A systematic review and meta-analysis , 2014, Scandinavian journal of gastroenterology.

[5]  Hiroshi Watanabe,et al.  Sitafloxacin‐based third‐line rescue regimens for Helicobacter pylori infection in Japan , 2014, Journal of gastroenterology and hepatology.

[6]  D. Graham,et al.  Eradication of gastric cancer is now both possible and practical. , 2013, Seminars in cancer biology.

[7]  Mahsa Khodadoostan,et al.  The Effects of Multistrain Probiotic Compound on Bismuth‐Containing Quadruple Therapy for Helicobacter pylori Infection: A Randomized Placebo‐Controlled Triple‐Blind Study , 2013, Helicobacter.

[8]  P. Xu,et al.  Adjuvant probiotics improve the eradication effect of triple therapy for Helicobacter pylori infection. , 2012, World journal of gastroenterology.

[9]  S. Valabrega,et al.  Helicobacter pylori eradication: sequential therapy and Lactobacillus reuteri supplementation. , 2012, World journal of gastroenterology.

[10]  R. Francavilla,et al.  Probiotics and Helicobacter pylori infection , 2012 .

[11]  F. Fabbian,et al.  Helicobacter pylori Infection in Clinical Practice: Probiotics and a Combination of Probiotics + Lactoferrin Improve Compliance, But Not Eradication, in Sequential Therapy , 2012, Helicobacter.

[12]  Gian Franco Gensini,et al.  Management of Helicobacter pylori infection—the Maastricht IV/ Florence Consensus Report , 2012, Gut.

[13]  A. Blum,et al.  Helicobacter pylori and probiotics. , 2007, The Journal of nutrition.

[14]  C. Hammerman,et al.  Safety of probiotics: comparison of two popular strains , 2006, BMJ : British Medical Journal.

[15]  C. O'Morain,et al.  Treatment of Helicobacter pylori Infection , 2006, Helicobacter.

[16]  R. Hunt,et al.  The Effect of CYP2C19 Polymorphisms on H. pylori Eradication Rate in Dual and Triple First-Line PPI Therapies: A Meta-analysis , 2006, The American Journal of Gastroenterology.

[17]  M. Tang,et al.  Probiotic use in clinical practice: what are the risks? , 2006, The American journal of clinical nutrition.

[18]  M. Ferrús,et al.  Antimicrobial peptides are among the antagonistic metabolites produced by Bifidobacterium against Helicobacter pylori. , 2005, International journal of antimicrobial agents.

[19]  H. Rautelin,et al.  Probiotic supplementation improves tolerance to Helicobacter pylori eradication therapy – a placebo‐controlled, double‐blind randomized pilot study , 2005 .

[20]  Maija Saxelin,et al.  Probiotic and other functional microbes: from markets to mechanisms. , 2005, Current opinion in biotechnology.

[21]  S. Salminen,et al.  In Vivo Safety Assessment of Two Bifidobacterium longum Strains , 2003, Microbiology and immunology.

[22]  A. Gasbarrini,et al.  A lyophilized and inactivated culture of Lactobacillus acidophilus increases Helicobacter pylori eradication rates , 2000, Alimentary pharmacology & therapeutics.